Literature DB >> 9722921

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells.

A J Zajac1, K Murali-Krishna, J N Blattman, R Ahmed.   

Abstract

The goal of therapeutic vaccination is to elicit an antiviral immune response within persistently infected individuals and consequently eradicate the infection. CD8+ T cells are potent mediators of viral clearance; however, during chronic infections CD4+ T cell help is required to sustain antiviral CD8+ T cell activity. Therapeutic vaccination should be targeted towards enhancing both CD4+ and CD8+ T cell virus-specific responses.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9722921     DOI： 10.1016/s0952-7915(98)80119-2

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  29 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice.

Authors:  J M Riberdy; J P Christensen; K Branum; P C Doherty
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 3.  T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus.

Authors:  Aaruni Khanolkar; Michael J Fuller; Allan J Zajac
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Aimin Tang; Ling Chen; Tong-Ming Fu; Robert K Evans; Mary-Ellen Davies; Daniel C Freed; William Hurni; Jose M Aste-Amezaga; Liming Guan; Romnie Long; Lingyi Huang; Virginia Harris; Denise K Nawrocki; Henryk Mach; Robert D Troutman; Lynne A Isopi; Krishna K Murthy; Karen Rice; Keith A Wilson; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 5.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

6.  T helper lymphocytes rescue CTL from activation-induced cell death.

Authors:  Richard Kennedy; Esteban Celis
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 7.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

8.  Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.

Authors:  Xiuli Zhang; Annie Issagholian; Eric A Berg; Jordan B Fishman; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection.

Authors:  Matthew F Cusick; Meiying Yang; Joan C Gill; David D Eckels
Journal:  Hum Immunol       Date:  2011-03-04       Impact factor: 2.850

10.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.